The two records describe separate ResearchAndMarkets.com market reports rather than the same underlying event. The Fabry disease treatment market is projected to grow from USD 2.63 billion in 2025 to USD 4.09 billion by 2031 at a 7.63% compound annual growth rate, supported by higher diagnosis rates, rare-disease screening, gene and mRNA therapy advances, and enzyme replacement therapy demand. The atrial fibrillation treatment devices market is projected to expand from $9.6 billion in 2026 to $29.0 billion by 2035 at a 13.1% CAGR, driven by aging populations, rising procedure volumes, pulsed field ablation, catheter ablation and left atrial appendage closure technologies. Both reports identify access, reimbursement, infrastructure and treatment-related challenges, while North America leads each market and Asia-Pacific is expected to grow fastest.